Am J Transplant, Volume 20, Suppl 3 Archives - Page 144 of 223 - ATC Abstracts

2020 American Transplant Congress
Empowering Recipients Through a Champion Program: A Life Saving Initiative
C. L. Rochon, D. Woch, K. Rancourt, O. K. Serrano, A. K. Asamoah
Transplantation, Hartford Hospital, Hartford, CT
*Purpose: Our purpose was to increase access to living donor kidney transplantation for patients referred at our center. With our interventions, our patients and their…
2020 American Transplant Congress
Living Donor Liver Transplantation for Unresectable Liver Confined Colorectal Liver Metastases: A North American Experience
L. I. Ruffolo, K. Dokus, M. Larye, J. Errigo, J. Bhoely, R. Dunne, M. Levstik, B. Al-Jadaibi, K. Tomiyama, R. Hernandez-Alejandro
Surgery, University of Rochester Medical Center, Rochester, NY
*Purpose: Colorectal cancer is the third leading cause of cancer related death, and 50% of patients will either present with synchronous or develop colorectal liver…
2020 American Transplant Congress
Donor Derived Transmissions 2018: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
M. Michaels¹, B. Plucinski², E. Ward², L. Strasfeld¹, M. Malinis¹, C. Ho¹, L. Danziger-Isakov¹, J. Bucio¹, G. Berry¹, M. Rana¹, C. Marboe¹, S. Aslam¹, R. Razonable¹, S. Pouch¹, G. F. Marklin¹, J. Levitsky¹, D. Levine¹, A. Agarwal¹, R. LaHoz¹
¹OPTN DTAC, Richmond, VA, ²UNOS, Richmond, VA
*Purpose: The OPTN DTAC, a multidisciplinary group, evaluates potential donor derived transmission events (PDDTE), mostly infections (I) & malignancies (M), to assess the likelihood of…
2020 American Transplant Congress
Three-Year Post-Transplant Outcome of Desensitized Mechanical Circulatory Support Patients Awaiting Heart Transplantation
J. Youn¹, R. Cole², D. Ramzy², E. Kim¹, J. Kobashigawa², J. Moriguchi²
¹Seoul St. Mary's Hospital, Seoul, Korea, Republic of, ²Cedars-Sinai Heart Institute, Los Angeles, CA
*Purpose: Up to 30% of durable mechanical circulatory support (MCS) patients (pts) develop panel reactive antibody (PRA) screen >= 10%. In our program, desensitization (DS)…
2020 American Transplant Congress
Proteomics and Metabolomics Technologies Reveal the Effect of Oxygen in Hypothermic Machine Perfusion to Alleviate Donation after Circulatory Death Liver Injury
X. Zeng¹, X. Fan², Y. Wang², Q. Xia¹, J. Liu¹, H. Li¹, Q. Ye², Z. Wang¹
¹Department of Urology, Union Hospital, Affiliated TongJi Medical College, Huazhong University of Science & Technology, Wuhan, China, ²Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Wuhan, China
*Purpose: To compare the effects of oxygenated and nitrogenated hypothermic machine perfusion on the preservation of donation after circulatory death (DCD) livers, and to explore…
2020 American Transplant Congress
microPOTS: A New Single Cell Proteomic Method for Profiling Human Kidney Transplant Biopsy Tissue
T. Sigdel¹, P. Piehowski², S. Roy¹, J. Liberto¹, A. Schroeder¹, P. Rashmi¹, S. Sur¹, I. Damm¹, W. Qian², M. M. Sarwal¹
¹University of California San Francisco, San Francisco, CA, ²Pacific Northwest National Laboratory, Richland, WA
*Purpose: The purpose of this study was to interrogate acute rejection (AR) in the renal allograft at single cell level. Despite advances in single cell…
2020 American Transplant Congress
Proposed New Kidney Allocation Policy: Moving to Concentric Circles as the First Unit of Allocation
A. Israni¹, S. Gustafson¹, A. Wey¹, B. Thompson¹, V. Casingal², M. Pavlakis³, S. Castro⁴, A. Wilk⁴, B. Kasiske¹, J. Snyder¹
¹SRTR, Minneapolis, MN, ²Carolinas Healthcare, Charlotte, NC, ³Beth Israel Deaconess, Boston, MA, ⁴UNOS, Richmond, VA
*Purpose: The Organ Procurement and Transplantation Network (OPTN) proposed a new national deceased donor kidney allocation policy that removes donor service area and OPTN region…
2020 American Transplant Congress
High-Activity Classical and Alternative Complement Pathway Genotypes – Association with Donor-Specific Antibody-Triggered Injury and Renal Allograft Survival
R. Reindl-Schwaighofer¹, B. Mezö², F. Eskandary¹, A. Heinzel¹, M. Wahrmann¹, K. Doberer¹, A. Heilos³, G. Bond¹, J. Kläger⁴, N. Kozakowski⁴, H. Haslacher⁵, R. Oberbauer¹, O. Viklický⁶, P. Hruba⁶, P. F. Halloran⁷, K. Rusai³, Z. Prohászka⁸, G. A. Böhmig¹
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary, ³Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria, ⁴Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁵Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁶Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁷Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada, ⁸Department of Medicine III, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary
*Purpose: Complement may contribute to donor-specific antibody (DSA)-triggered transplant injury. Here, we investigated whether the intrinsic strength of classical (CP) and alternative complement pathways (AP)…
2020 American Transplant Congress
Improvement in Long Term Kidney Transplant Survival Most Dramatic among Minorities, Diabetics and Older Patients
E. D. Poggio¹, S. Arrigain², A. Wee³, D. C. Brennan⁴, J. D. Schold²
¹Nephrology, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Urology, Cleveland Clinic, Cleveland, OH, ⁴Nephrology, Johns Hopkins, Baltimore, MD
*Purpose: Short-term and long-term kidney transplant graft survival has been improving over time, but whether this improvement in outcomes is more pronounced in the early…
2020 American Transplant Congress
Multi-Center, Open-Label Trial of Pre-Emptive Glecaprevir/Pibrentasvir (G/P) to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus (MYTHIC)
M. Sise¹, D. Goldberg², J. Kort³, D. Schaubel⁴, R. Alloway⁵, C. Durand⁶, R. Fontana⁷, J. Friedewald⁸, R. Brown⁹, S. Prenner¹⁰, R. Landis⁴, P. Reese¹¹, R. Chung¹
¹Internal Medicine - Nephrology, MGH, Boston, MA, ²Hepatology and Transplantation, U Miami, Miami, FL, ³Abbvie, Chicago, IL, ⁴Department of Biostatistics, U Penn, Philadelphia, PA, ⁵Department of Internal Medicine - Nephrology and Hypertension, U Cincinnati, Cincinnati, OH, ⁶Department of Medicine, JHU, Baltimore, MD, ⁷Internal Medicine - Gastroenterology, U Michigan, Ann Arbor, MI, ⁸Internal Medicine - Nephrology and Hypertension, Northwestern, Chicago, IL, ⁹Internal Medicine - Hepatology, Weill Cornell, NYC, NY, ¹⁰Internal Medicine - Gastroenterology, U Penn, Philadelphia, PA, ¹¹Transplant Nephrology, U Penn, Philadelphia, PA
*Purpose: Kidneys from Hepatitis C virus (HCV)-infected deceased donors continue to be discarded at high rates despite small, successful studies of HCV-viremic donors into uninfected…